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Abstract
Chronic urticaria (CU), one of the most frequent skin disorders, is defined as the repeated 
occurrence of red, swollen, itchy and sometimes painful hives (wheals), and/or 
 angioedema (swellings in the deeper layers of the skin), for more than 6 weeks [1, 2]. 
CU has an estimated worldwide prevalence of approximately 1% [3], which includes 
spontaneous and inducible types. In chronic spontaneous urticaria (CSU), the most 
common type of CU, symptoms occur without a specific trigger [1, 3]. In contrast, in 
chronic inducible urticaria (CIndU), symptoms occur in response to specific stimuli, such 
as exposure to cold, heat or pressure [4]. Patients may suffer from CSU and CIndU in 
parallel [2]. Chronic urticaria (CU) is defined as the repeated occurrence of red, swol‐
len, itchy and sometimes painful wheals, and/or angioedema, for more than 6 weeks. 
CU includes spontaneous and inducible types. In chronic spontaneous urticaria (CSU), 
the most common type of CU, symptoms occur without a specific trigger. Treatment 
of urticaria and/or angioedema mainly consist of antihistamines, short courses of corti‐
costeroids, other immunosuppressive, and anti‐inflammatory agents. Angioedema is a 
deeper  expression of urticaria which is classified by allergic, hereditary, acquired, and 
angiotensin‐ converting enzyme inhibitor (ACEI)‐induced forms.
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1. Introduction
H1 antihistamines are usually effective in the majority of urticaria and/or angioedema patients 
but might be insufficient in some patients. Second‐generation antihistamines are safe and 
effective in patients with urticaria and are the first‐line agents in all guidelines. For patients 
not responding to monotherapy with a second‐generation antihistamine in the second step, 
several treatments can be used including higher doses of second‐generation antihistamines, 
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addition of H2 antagonist, or leukotriene receptor antagonists. First‐generation antihista‐
mines like hydroxyzine or doxepin can be considered in patients whose symptoms remain 
uncontrolled in bed time. Systemic corticosteroids are frequently used for refractory patients 
with urticaria and might be considered in some patients for only short‐time use. Alternative 
therapies including omalizumab are approved by the Food and Drug Administration (FDA) 
for patients with chronic refractory urticaria and cyclosporine. Anti‐inflammatory agents 
including dapsone, sulfasalazine, hydroxychloroquine, and colchicine have been used in 
some patients with limited evidence for efficacy in chronic urticaria.
Acute attacks of HAE are unresponsive to antihistamines or corticosteroids. C1‐INH 
 replacement, plasma kallikrein inhibitor, bradykinin receptor antagonist, and fresh frozen 
plasma have been approved for the treatment of acute attacks. Angioedema caused by ACE 
inhibitors can be an acute emergency with laryngeal or tongue edema. There is no response 
to antihistamines or corticosteroids. Fresh frozen plasma, C1 inhibitor, and bradykinin recep‐
tor antagonist appear to be safe and effective therapeutic options for the management of 
ACEI‐induced angioedema.
2. Management of urticaria
Urticaria is commonly defined as the sudden appearance of wheals that are typically pruritic 
and resolve within 24 h without any skin changes, although some lesions may last up to 48 h 
[1]. The updated classification of urticaria distinguishes acute and chronic urticaria. Acute 
urticaria is defined as the one persisting less than 6 weeks, whereas chronic urticaria (CU) 
persists for at least 6 weeks [1]. Chronic urticaria is spontaneous (CSU) or inducible (CIU) 
[2]. CSU is a common disorder with a prevalence of 1% that is characterized by recurrent 
wheals, angioedema, or both for more than 6 weeks (with or without free intervals). CSU is 
self‐ limited but in many patients, symptoms recur for several years and can be refractory to 
standard therapies [3, 4].
The international urticaria guidelines advise standard dose, second‐generation  H1‐ antihistamines 
as first‐line therapy [5]. However, H1 antihistamine treatment leads to absence of symptoms 
in fewer than 50% of patients, and in about 10% of cases, they fail to  control the disease even 
at higher than licensed doses [5, 3]. Up‐dosing of second‐ generation H1 antihistamines (up 
to fourfold), as recommended by the urticaria guideline as second‐line therapy, can improve 
response, but many patients remain symptomatic. The urticaria guideline recommends add‐
on omalizumab, cyclosporin A (CsA) or montelukast third line in patients with an inadequate 
response to high‐dose H1 antihistamines [5]. In refractory patients, short courses of oral steroids 
may induce a remission in about 50% of cases [3]. Other approaches include intravenous immu‐
noglobulin, rituximab, dapsone, and anticoagulants are also limited by paucity of data on their 
efficacy and adverse effect profile [3, 6].
According to guidelines prepared in accordance with data obtained mostly in adult studies, 
the primarily preferred drug in acute and chronic urticaria exacerbations in children is second‐
generation H1 antihistamines. Guidelines recommend that the dose should be increased three 
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or fourfold in cases where response to H1 antihistamines treatment is not obtained at normal 
doses. If success of therapy cannot be achieved with H1 antihistamines used at the usual dose, 
high‐dose H1 antihistamines is recommended. It has been reported that  corticosteroids may 
be used short term (up to 10 days) in periods of urticaria exacerbations. However, guidelines 
also state that a definite recommendation cannot be made because there are insufficient ran‐
domized controlled studies in this area. The primary treatment option in long‐term treatment 
of chronic urticaria is again second‐generation nonsedative H1 antihistamines. However, 
the number of randomized controlled studies is substantially low for evidence‐based rec‐
ommendations in children. In patients who do not respond to high‐dose H1 antihistaminic 
treatment, corticosteroid, omalizumab, cyclosporin A, and montelukast constitute tertiary 
treatment options. However, these drugs are recommended only in eligible patients because 
of the adverse effects and costs of these drugs [7].
It is clear that the current evidence‐based treatment algorithm does not fit every urticaria 
patient. It is important that physicians do not just consult the algorithm but read the guideline 
line by line and employ an individualized approach for the care of each patient.
2.1. H1 antihistamines
Current international guidelines recommend a licensed dose of second‐ or third‐ generation 
(non‐sedating) antihistamines for the treatment of all forms of urticaria as the first‐line 
therapeutic option. Second‐generation H1 antihistamines include fexofenadine, loratadine, 
and cetirizine. Third‐generation antihistamines include desloratadine and levocetirizine. 
These medications should be taken continuously at the lowest necessary dose rather than 
on demand. This treatment with licensed doses of H1 antihistamines leads to an absence of 
symptoms in fewer than 50% of patients with CSU [5].
If CSU symptoms persist after 2 weeks of treatment with licensed doses of second‐generation 
H1 antihistamines, it is recommended to increase the dose up to four times the licensed dose 
instead of combining different H1 antihistamines to obtain control as a second‐line treatment. 
But there are only few controlled studies that have assessed the efficacy and safety of  non‐
sedating antihistamines [5, 6]. This dose increase results in a higher degree of efficacy in some, 
but not all, patients, with up to one‐third of patients remaining symptomatic [5].
First‐generation H1 antihistamines (diphenhydramine and hydroxyzine) are lipophilic 
compounds which cross the blood‐brain barrier and therefore sedating and anticholinergic 
side effects. They impair cognitive function, learning, and performance. First‐generation 
H1 antihistamines have been advocated for use by the US guidelines as step two therapy 
at night and can be titrated up to higher doses as step three therapy if tolerated by the 
patient. Non‐sedating second‐ and third‐generation H1 antihistamines have lower pro‐
pensity to cross the blood‐brain barrier. Because of this, non‐sedating H1 antihistamines 
are favored [6].
In studies mentioned above, higher‐than‐standard doses of antihistamines were not 
 associated with an increase in adverse effects in most cases. Antihistamines also have anti‐ 
inflammatory effects in the treatment of urticaria when used at higher doses than licensed 
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doses.  Anti‐ inflammatory activity may result from the activation of genes responsible for the 
synthesis and/or synthesis of pro‐inflammatory mediators [6].
2.2. H2 antihistamines
H2 antihistamines such as cimetidine and ranitidine are more typically used as add‐on ther‐
apy in combination with H1 antihistamines and leukotriene receptor antagonists (LTRAs). 
A review of the Global Urticaria Forum’s attendees’ opinions suggested that although these 
agents are old and generally well tolerated by patients, they are unlikely to be used in clinical 
practice [8].
2.3. Leukotriene receptor antagonists
Cysteinyl leukotrienes are potent pro‐inflammatory mediators, the effects of which can be 
blocked by LTRAs such as montelukast, zafirlukast, and pranlukast. LTRAs are recommended 
as add‐on step two therapies by the US guidelines and in the third step in the Europe Union’s 
(EU) guidelines. LTRAs have been found to significantly improve CU symptoms when used 
in conjunction with H1 antihistamines but are not as effective as H1 antihistamines when 
used as monotherapy. Combination therapy of antihistamines plus LTRAs may be more 
effective in patients with aspirin and nonsteroidal anti‐inflammatory drug‐exacerbated CSU. 
LTRAs appear to be well tolerated, with a good side‐effect profile. Montelukast is not cur‐
rently licensed for the treatment of CSU [1, 5, 9, 10].
2.4. Third‐line treatments
If a patient’s CSU symptoms persist after 1–4 weeks of second‐line treatment, add‐on 
 omalizumab, CsA, or montelukast are recommended as third‐line options. Both omalizumab 
and CsA are effective third‐line CSU treatments; montelukast appears to have lower efficacy 
in this setting.
2.5. Omalizumab
Omalizumab, a humanized recombinant immunoglobin (Ig) G1 kappa monoclonal anti‐IgE, is 
effective in antihistamine‐unresponsive patients although optimal treatment duration needs 
to be defined [3]. Omalizumab is currently the only agent licensed for the third‐line treatment 
of CSU [8]. The FDA approved the omalizumab for CU is 150 to 300 mg subcutaneously every 
4 weeks. The clinical response starts after 1 week at the earliest, and the complete response can 
be prolonged up to 4–6 months. Studies found that complete control in approximately one‐
third of patients, partial control in another one‐third, and one‐third were unresponsive [1].
Omalizumab carries a label warning for anaphylaxis, although no cases of anaphylaxis were 
reported in the phase III trials of omalizumab in CSU. Other known risks associated with 
omalizumab include increased risks of cardiac and neurovascular events and a controversial 
increased risk of lymphoma. Omalizumab is generally well tolerated in patients with CSU 
and is rated as pregnancy category B [5, 1].
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2.6. Cyclosporin A
Cyclosporin A (CsA) could be a suitable drug for the treatment of CSU as it directly inhibits mast 
cell degranulation as well as targeting T‐cells. Similarly, CsA directly inhibits part of the basophil 
histamine release assay (BHRA) [5]. Response of autoreactive CSU to CsA has been associated 
with disappearance of autoantibodies and CsA may be disease‐modifying in these patients [5]. 
A low‐dose CsA treatment (3 mg/kg per day or less) has been shown to cause full remission of 
symptoms in a number of different randomized controlled trials and real‐world studies [11–14].
CsA is also effective in the majority of antihistamine‐resistant CSU patients, but its use is 
limited by potential side effects [3]. The most common adverse events associated with the use 
of CsA include hypertension, fatigue, gastrointestinal problems, and headache [15]. It is also 
thought that long‐term use of CsA may be responsible for the development of non‐melanoma 
skin cancer [16]. In patients receiving CsA therapy, monitoring of blood pressure and renal 
function is particularly important [13]. CsA is not currently licensed for the treatment of CSU 
and should be preferred only as a short‐term treatment option [5].
Cyclosporin has been reported to be effective in some studies of CSU, including three 
 double‐blind [12–18], and one study reported that 40% of patients achieved complete remis‐
sion in 9 months [18].
2.7. Other treatment options
Other possible options for the treatment of CSU are anti‐inflammatory medications 
( hydroxychloroquine, dapsone, sulfasalazine, and colchicine) and immunosuppressants 
(mycophenolate, tacrolimus, azathioprine, and methotrexate) supported by low levels of 
evidence as defined by the Grading of Recommendations Assessment, Development, and 
Evaluation (GRADE) system (Table 1).
Drug Quality of evidence Strength of recommendation
H2 antihistamines Moderate Weak (+)
Oral corticosteroids (short course) Low Weak (+)
Oral corticosteroids Very low Strong (−)
Anti‐inflammatory agents (dapsone, 
sulfasalazine, hydroxychloroquine, 
colchines, mycophenolate mofetil)
Low–very low Weak (+)
Immunosuppressive agents Very low Weak (+)
Methotrexate
Cyclophosphamide
Intravenous Ig Low Weak (+)
(+) recommendation for medication, (−) recommendation against medication, and Ig: immunoglobulin
Table 1. Quality of evidence and strength of recommendation for use of intervention in CSU based on the GRADE 
system.




In the current international urticaria guideline, the use of dapsone and its effectivity is still 
unclear. However, in a double‐blind, placebo‐controlled study, dapsone has been reported 
as a promising agent in patients with CSU unresponsive to antihistamines [19]. Supportive 
evidence is needed to recommend the use of dapsone in urticaria patients [8].
2.9. Azathioprine
Additional new therapies such as azathioprine are under investigation for use in urticaria, 
although the evidence supporting their use is currently limited and not robust enough to 
 warrant a change in current guidance [8].
2.10. Corticosteroids
Oral corticosteroids are commonly used in management of acute urticaria, and prednisone 
has been shown to significantly improve control of symptoms compared to antihistamines 
alone. Short courses (10 days–3 weeks) of corticosteroids may be used at any time if disease 
exacerbations are required in CU [5, 1].
3. Management of angioedema
Although both urticaria and allergic angioedema are associated with mast cell activation, 
there are many differences between them. While urticaria affects the skin, angioedema usu‐
ally affects the mucosal tissue as well. In addition, middle and papillary dermis are involved 
in urticaria, whereas reticular dermis and submucosal tissues are involved in angioedema. 
Angioedema usually resolves in less than 24–48 h, disappear without aftereffects and are 
more painful than itchy [20, 2, 1].
Most cases of angioedema are attributable to the histamine and bradykinin. Histamine‐
mediated (allergic) angioedema occurs through a type I hypersensitivity reaction, 
whereas bradykinin‐mediated (non‐allergic) angioedema is iatrogenic or hereditary 
in origin. Bradykinin‐mediated angioedema is divided into three distinct types: 
 hereditary a ngioedema (HAE), angiotensin‐converting enzyme inhibitor (ACEI)‐induced 
 angioedema, and acquired angioedema (AAE) [20] (Table 2). Although their clinical 
 presentations bear similarities, the treatment algorithm differs significantly from each 
other. Corticosteroids and epinephrine are effective only in the management of  histamine‐
mediated angioedema [20].
Priority of the treatment of angioedema is to provide airway protection. Intramuscular epi‐
nephrine may be required in the presence of acute laryngeal edema or anaphylaxis. It is 
administered in adult patients at doses of 1:1000 mg 0.2–0.5 mg and in children at doses 
of 0.01 mg/kg (up to 0.03 mg). These doses may be repeated at intervals of 5–15 min and if 
 necessary with monitoring [20].
A Comprehensive Review of Urticaria and Angioedema98
3.1. Hereditary angioedema
Hereditary angioedema (HEA) is a rare, autosomal dominant disorder characterized by 
a quantitative (type I) or qualitative (type II) deficiency of C1 esterase inhibitor (C1‐INH) 
 protein. HAE with normal C1‐INH (type III) occurs because of one of two known mutations 
in the gene for factor XII [20].
3.2. C1‐INH replacement therapy
C1‐INH replacement therapy maintains a central role for the treatment of angioedema attacks 
in patients with HAE. Berinert is a purified, pasteurized, and lyophilized form of C1‐INH 
Angioedema type Clinical and diagnostic features
Histamine mediated
Allergic angioedema Angioedema is usually accompanied by urticaria and sometimes 
anaphylaxis, may be pruritic, and is associated with exposure to allergens; 
attacks last for 24–48 h; it is responsive to antihistamines and corticosteroids
Angioedema with urticarial vasculitis Angioedema may accompanied by urticaria; there may be petechiae or 
purpura after swelling resolves; symptoms of underlying vasculitis
Bradykinin mediated
Hereditary angioedema types I and II Recurrent attacks without urticaria; erythema marginatum is a cardinal 
finding; onset of the disease in childhood or young adulthood, worsens 
at puberty; family history in 75% of patients; attacks unresponsive to 
antihistamines or corticosteroids
Hereditary angioedema type III Associated with mutations in factor XII, more common in women, may 
be estrogen dependent, typical onset after childhood, face and tongue 
extremity involvement is more frequent than abdominal, recurrent tongue 
swelling is a cardinal symptom, more disease‐free intervals than in HAE 
types I and II, family history of angioedema, and attacks are unresponsive to 
antihistamines or corticosteroids
Acquired angioedema Attacks are similar to HEA, onset in middle age or later, no family history, 
attacks unresponsive to antihistamines or corticosteroids
ACE inhibitor‐induced angioedema History of ACE inhibitor use, no urticaria, face and tongue are the most 
frequent sites, more common in blacks and smokers, patients usually can 
tolerate ARBs
Not mediated by histamine or bradykinin
Idiopathic angioedema Angioedema sometimes accompanied by urticaria, swelling may persist for 
up to 48 h, attacks may occur daily, patients are responsive to antihistamines 
or corticosteroids
Pseudoallergic angioedema Urticaria is typically present, usually a class‐specific reaction thought 
to be mediated by cysteinyl‐leukotriens and includes NSAİD‐induced 
angioedema, which occurs because of cyclooxygenase inhibition and 
subsequent release of cysteinyl‐leukotriens
ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti‐inflammatory drug.
Table 2. Clinical and diagnostic features of various types of angioedema.
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concentrate which is derived from human plasma. It was approved by the US FDA in 2009 for 
the treatment of acute abdominal, facial, and, more recently, laryngeal attacks of HAE in adult 
and adolescent patients [20]. It is approved in the European Union and the USA for adults and 
adolescents (≥13 years of age) for the treatment of acute angioedema attacks in patients with 
HEA due to C1‐INH deficiency [21] (Table 3).
3.3. Plasma kallikrein inhibitor
Ecallantide (Kalbitor) received FDA approval in 2009 for use in the treatment of acute exacer‐
bations of HEA in people aged 16 years and more. However, the EU rendered a negative opin‐
ion regarding its approval. Ecallantide can be used against attacks of HAE at any anatomical 
location, including abdominal/gastrointestinal, laryngeal, and peripheral attacks [22] (Table 3).
3.4. Bradykinin receptor antagonist
Icatibant (Firazyr) is a highly selective competitive bradykinin β2 receptor antagonist, and it 
is available as 30 mg in 3‐ml solution as a ready‐to‐use syringe for immediate subcutaneous 
injection in an HAE attack [20] (Table 3).
Therapy and indication Dosage Monitoring tests
C1 esterase inhibitor [human] 
(Berinert; CSL Behring)
20U/kg body weight IV at a rate of 
4 ml/min
Monitor patients with known risk 
factors for thrombotic events
Indicated for the treatment of acute 
abdominal or facial attacks of HEA in 
adult and adolescent patients
Epinephrine should be immediately 
available to treat any acute severe 
hypersensitivity reactions following 
discontinuation of administration
Plasma kallikrein inhibitor (kalbitor 
[ecallantide]; Dyax Corb)
30 mg (3 ml) SC in three 10‐mg (1 ml) 
injections
Given the similarity in 
hypersensitivity symptoms and acute 
HAE symptoms, monitor patients 
closely for hypersensitivity reactions
Indicated for attacks at all anatomic 
sites
If attack persists, additional dose of 
30 mg (3 ml) may be administered 
within a 24‐h period
Administer in a setting equipped to 
manage anaphylaxis and HEA
Fresh frozen plasma 2U at 1–12 h before the event (only 
for use when C1‐INH concentrate is 
not available)
Baseline, liver function test, hepatitis 
virology
Bradykinin β2 receptor antagonist 30 mg (3 ml) injected SC in the 
abdominal area.
For patients who never received 
Firazyr previously, the first treatment 
should be given in a medical 
institution or under the guidance of 
a physician
(Fizary [Icatıbant] Shire Orphan 
Therapies)
If attack persists, additional injections 
of 30 mg (3 ml) may be administered 
at intervals of ≥ 6h
Indicated for attacks at all anatomic 
sites
No more than 3 injections in 24 h
C1‐INH, C1 esterase inhibitor; IV, ıntravenously; SC, subcutaneously.
Table 3. Treatment options of hereditary angioedema.
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3.5. ACE inhibitor‐induced angioedema
ACEI‐induced angioedema is due to excessive accumulation of bradykinin. ACEI‐induced 
angioedema is most commonly present with swelling of face, lips, tongue, and larynx and 
rarely involves visceral organs. Urticaria and itching are notably absent. Life‐threatening 
edema of the upper airway is present in 25–39% of cases of ACEI‐induced angioedema. 
Although ACEI‐induced angioedema most commonly occurs shortly after treatment is 
 initiated, it can develop long after treatment has started [20]. The nonallergic nature of the 
 reaction renders traditional therapies (corticosteroids and antihistamines) as ineffective. 
Fresh frozen plasma, C1 inhibitor, and icatibant appear to be safe and effective therapeutic 
options for the management of ACEI‐induced angioedema [22].
4. Management of anaphylaxis
Anaphylactic findings may include diffuse urticarial plaques, angioedema,  gastrointestinal 
symptoms, and hypotension. In severe forms of anaphylaxis, loss of consciousness 
due to vascular collapse may develop. Pulmonary symptoms such as hyperinflation, 
 peribronchial obstruction, and submucosal edema are frequently observed during ana‐
phylaxis [20].
Elevation of lower extremities and placing in a supine position of the patient ( semi‐ reclining 
if dyspneic or vomiting) are recommended [23]. An important component of acute man‐
agement of anaphylaxis is volume expansion. The largest catheter possible should be 
placed on the largest peripheral vessel, and the rate should be titrated  according to pulse 
and blood pressure. Adults are infused with 1–2 L iv of normal saline (5–10 mL/kg in the 
first 5 min) and 30 mL/kg iv in the first h in children. Antihistamines act slower than epi‐
nephrine and should not be administered alone in the treatment of anaphylaxis or acute 
allergic angioedema. The combined use of H1 and H2 blockers is more effective than 
the H1 antihistamines alone. Diphenhydramine should be administered to 25–50 mg iv 
in adults and 1 mg/kg iv (up to 50 mg) in children. Similar oral doses may be sufficient 
for mild episodes. Ranitidine should be infused 1 mg/kg iv in adults, 12.5–50 mg, iv for 
10 min, in children. Inhaled β2 agonists are useful when bronchospasm is resistant to 
epinephrine injection alone. Systemic corticosteroids are not sufficient to prevent anaphy‐
laxis. Although the use of parenteral corticosteroids (iv methylprednisolone) provides a 
benefit in histamine‐mediated angioedema, the therapeutic effect is not immediate [20]. 
Epinephrine is the first choice as recommended in all guidelines. It is recommended to 
inject from an autoinjector IM in the mid‐outher of the thigh. The first‐aid dose of epi‐
nephrine is 0.01 mg/kg of a 1 mg/mL (1:1000) dilution to a maximum dose of 0.5 mg in 
an adult or 0.3 mg in a child. This dose can be repeated every 5–15 min as needed [24]. 
Intravenous epinephrine (0.1 mg in 100 mL saline, 1:100.000 solution, initially at a rate of 
30–100 mL/h) may be administered in cases that do not respond to recurrent epinephrine 
injection and fluid therapy. Hemodynamic monitoring is recommended during intrave‐
nous epinephrine therapy [23].
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